The Flowr Corporation is still very much committed on the facilities located in Portugal, which are owned and operated by Flowr’s wholly-owned subsidiary, Holigen Holdings Limited.
“We still firmly believe that Holigen’s team and assets are a unique entry point into the European Union. The Sintra facility is one of very few E.U. GMP certified facilities on the continent. If a competitor wanted to enter the E.U. today they would face long lead times on regulatory approvals, construction, importation of genetics, and assembly of a quality team with the requisite experience to be successful. With the relocation of Tom Flow to Portugal and our partnership with Cookies Creative Consulting and Promotions, we believe that Holigen is poised for great success in the near term,” commented Darryl Brooker, Chief Executive Officer of Flowr. “There are several reasons to be in Portugal – the regulatory landscape is changing, the cost structure is highly competitive and there are no real competitors in the premium cannabis market yet.”
“I have been involved in the planning, construction and operation of several of the world’s premier cannabis facilities and the Sintra facility is undoubtedly one of the best facilities in the world to grow premium, high THC cannabis,” commented Tom Flow, co-founder of Flowr and Chief Operating Officer. “In Portugal, I see not only a growing medical cannabis market but the discussions around an adult use regime are also very encouraging. At Holigen, we have built a facility that will be able to cater to both a medical cannabis regime by providing patients with consistent, high-quality product but we are also looking ahead to when there may be an adult use market and having a partnership with Cookies also lets us be ready for that change.”
Holigen expects to harvest approximately 300 kilograms of medical cannabis in the first quarter of 2022 and over 2,000 kilograms of premium cannabis per year from the Sintra facility. Holigen is the final stages of cultivating BC Black Cherry and BC Strawnana strains, having completed its first harvest of BC Black Cherry and BC Strawnana at its purpose-built indoor facility in Sintra, Portugal. Initial in process testing for both genetics of medical cannabis are indicating high THC content levels of greater than 25%.
In addition, Holigen is commencing accelerated and long-term stability testing on these strains with a view to having them in market under its own brand in multiple markets in the second half of 2022. In the meantime, Holigen is pursuing business-to-business medical cannabis bulk sales as a way to get product into multiple markets, and to generate immediate revenue.
Flowr
www.flowr.ca